Detalhe da pesquisa
1.
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.
Immunity
; 57(3): 541-558.e7, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38442708
2.
PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.
Nat Commun
; 14(1): 7825, 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030622